Case report: Blepharospasm in peak-dose dyskinesia may benefit from amantadine in Parkinson's disease
Qian-Ya Fan, Xiao-Dong Zhang, Ze-Di Hu and 5 more
Frontiers in Neurology · 2022
doi:10.3389/fneur.2022.961758 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
IntroductionBlepharospasm is uncommon in Parkinson's disease, especially in the peak-dose dyskinesia period.Case presentationWe herein present the case of a patient with PD who developed blepharospasm in the peak-dose dyskinesia period. The symptom was improved by taking amantadine.ConclusionThe current report expands the phenomenology of peak-dose dykinesia in PD to include dystonic blepharospasm. This complication of levodopa therapy may respond to amantadine despite the dystonic appearance of movements.
Abstract licence: CC BY
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.